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Objective: With emergence and geographically expanding of antimalarial resistance worldwide, molec-
ular markers are essential tool for surveillance of resistant Plasmodium parasites. Recently, single-
nucleotide polymorphisms (SNPs) in the PF3D7_1343700 kelch propeller (K13-propeller) domain are
shown to be associated with artemisinin (ART) resistance in vivo and in vitro. This study aims to
investigate the ART resistance-associated polymorphisms of K13-propeller and PfATPase6 genes in Plas-
modium falciparum isolates from Bioko Island, Equatorial Guinea (EG).
Methods: A total of 172 samples were collected from falciparum malaria patients on Bioko Island be-
tween 2013 and 2014. The polymorphisms of K13-propeller and PfATPase6 genes were analyzed by Nest-
PCR and sequencing.
Results: Sequences of K13-propeller and PfATPase6 were obtained from 90.74% (98/108) and 91.45% (139/
152) samples, respectively. The 2.04% (2/98) cases had non-synonymous K13-propeller A578S mutation
but no found the mutations associated with ART resistance in Southeast Asia. For PfATPase6, the muta-
tions were found at positions N569K and A630S with the mutation prevalence of 7.91% (11/139) and
1.44% (2/139), respectively. In addition, a sample with the mixed type at position I723V was discovered
(0.72%, 1/139).
Conclusions: This study initially offers an insight of K13-propeller and PfATPase6 polymorphisms on
Bioko Island, EG. It suggests no widespread ART resistance or tolerance in the region, and might be
helpful for developing and updating guidance for the use of ART-based combination therapies (ACTs).
© 2016 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The emergence of Plasmodium falciparum resistance to antima-
larial drugs has been threatening the world's malaria control and
elimination efforts (Young et al., 1963). Currently, P. falciparum havey and Embryology, Shantou
Guangdong Province 515000,
；fax: þ86 0754 88557562 3.
Ltd on behalf of Australian Society fdeveloped resistance/tolerance to antimalarial drugs chloroquine
(CQ) and sulfadoxine-pyrimethamine (SP). Although World Health
Organization (WHO) has recommended artemisinin (ART)-based
combination therapies (ACTs) as the ﬁrst-line treatment for un-
complicated P. falciparum malaria, P. falciparum are becoming
insensitive to ART and its derivatives (Harinasuta et al., 1965;
Wongsrichanalai et al., 2002; Amaratunga et al., 2014). At pre-
sent, virtually all malaria endemic countries in sub-Saharan Africa
are adopting either Artemether-Lumefantrine (AL) or Artesunate-
Amodiaquine (AS-AQ) as the front-line ACTs. AS-AQ and the ART
derivative dihydroartemisinin-piperaquine (DP) are used inor Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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Emerging evidence indicate that P. falciparum has been devel-
oping the resistance to ART and its derivatives. In Pailin of western
Cambodia and other Southeast (SE) Asia area, parasite clearance
was delayed following the treatment with ART monotherapy or
ACTs (Noedl et al., 2008; Dondorp et al., 2009; Amaratunga et al.,
2012; Miotto et al., 2013; Ashley et al., 2014). Our recent study
showed the presence of high prevalent mutations in Pfmdr1
(91.39%) and Pfcrt (98.67%) which markers for antimalarial drug
resistence in P. falciparum clinical isolates on Bioko Island, EG (Li
et al., 2015). It is globally threatening for malaria prevention and
treatment (Wootton et al., 2002; Roper et al., 2004). It is imperative
to conduct surveillances to identify areas that are potentially
developing drug resistance.
Several molecular markers for antimalarial drug resistance has
been identiﬁed (Wongsrichanalai et al., 2002; Barrette and
Ringwald, 2010). Polymorphisms of the sarcoplasmic/endo-
plasmic reticulum Ca2þ-ATPase ortholog in P. falciparum (PfSERCA
or PfATPase6) has been associated with ART resistance, although
the association of SNPs in PfATPase6 with resistance to ART and
the underlying mechanism remains to be conﬁrmed (Jambou
et al., 2005; Afonso et al., 2006; Mugittu et al., 2006; Cui et al.,
2012).
Single-nucleotide polymorphisms (SNPs) in the PF3D7_1343700
kelch propeller (K13-propeller) have been identiﬁed to be a key
causal determinant of ART resistance in SE Asia (Mok et al., 2015).
From2009 to 2015, a series of studies associatedwith K13-propeller
has been published particular in Asia (Talundzic et al., 2015; Tun
et al., 2015; Wang et al., 2015) and WHO Africa region (Cooper
et al., 2015; Ouattara et al., 2015). In Africa, limited mutations of
K13-propeller were found in Dakar (Torrentino-Madamet et al.,
2014), Uganda (Cooper et al., 2015), Mali (Ouattara et al., 2015),
and even 12 countries from sub-Saharan Africa (Kamau et al., 2015).
These studies showed the mutational loci in African countries were
different from those of SE Asia (Kamau et al., 2015).
Malaria is a serious health problem in EG, especially on Bioko
Island. However, whether the ART resistance has been developed
on the Bioko Island remains unclear. In this study, we surveyed
polymorphisms in K13-propeller and PfATPase6 genes in clinical
isolates collected from Bioko Island, EG. Our ﬁndings may provide a
clue to prevent and treat malaria using ART on Bioko Island, EG.2. Materials and methods
2.1. Study area
Bioko Island belongs to EG and is located in the Gulf of Guinea,
about 100 km off the coast of southern Nigeria and 160 km
northwest of continental EG (Fig. 1). The island has a population of
266 000 inhabitants (2001 census) and a humid tropical environ-
ment. The launch of the Bioko Island Malaria Control Project
(BIMCP) have had a marked impact on malaria transmission, ma-
laria due to P. falciparum is still the major public health problem on
the island. The entomological inoculation rates (EIRs) in Bioko Is-
land ranged from 163 to 840, with the outdoor EIRs reaching more
than 900 infective mosquito bites yearly and a malaria prevalence
of 52% under the age of ﬁve years (Overgaard et al., 2012; Rehman
et al., 2013).2.2. Samples collection
Blood samples (3 ml) were collected from the conﬁrmedmalaria
cases between September 2013 and March 2014. Approximately
300 ml of blood was aliquoted on 3 MM Whatman® ﬁlter paper(Whatman International Ltd., Maidstone, England), and air dried.
These ﬁlters were then stored individually in Ziplock bags con-
taining silica desiccant beads and kept at 20 C. These samples
were examined using the ICT malaria P.f. Cassette Test (ICT Di-
agnostics, South Africa) and Giemsa-stained thick and thin pe-
ripheral blood smear examination with microscope. For quality
control, archived malaria positive slides were re-examined and
parasitaemia was recorded. The Plasmodium spp. was conﬁrmed by
Plasmodiummalaria real time PCR diagnostic kit (Shanghai Liferiver
Bio-Tech Corp, China). This study was approved by the ethics
committees of Malabo Regional Hospital. The informed consent
was obtained from all participated subjects.
2.3. DNA extraction from blood samples
Genomic DNA (gDNA) was extracted from dried ﬁlter blood
spots (DBS) by following Chelex-100 extraction procedure
described in our previous report (Li et al., 2014). An 18S-rRNA-
based RT-PCR was used to evaluate the quality of P. falciparum
gDNA.
2.4. Genotyping
Nucleotide and amino-acid sequence of K13-propeller and
PfATPase6 used in current study has been reported in PlasmoDB
(http://plasmodb.org) under Gene ID: PF3D7_1343700 and
PF3D7_0106300. In order to illustrate the mutations of K13-pro-
peller and PfATPase6, one segment of K13-propeller gene and one
fragment from PfATPase6 gene were ampliﬁed by a nested PCR
(Zhang et al., 2008; Li et al., 2014), respectively.
The K13-propeller and PfATPase6 genes were ampliﬁed by nested
PCR using the primers in Table 1. For ﬁrst round PCR, 0.5 ml of DNA
was ampliﬁed with 10 ml 2  NovoStar Green PCR Mix (1.25 U/ml
NovoStar Taq DNA Polymerase, 0.4 mM dNTP Mixture, 2  PCR
Buffer, and 4 mM Mg2þ), 0.5 ml forward primer (10 mM), 0.5 ml
reverse primer (10 mM), and sterile ultrapure water to a ﬁnal vol-
ume of 20 ml. For the second round PCR, 0.5 ml primary PCR products
were ampliﬁed with 40 ml reaction system, including 20 ml
2  NovoStar Green PCR Mix, 1.0 ml forward primer (10 mM), 1.0 ml
reverse primer (10 mM), and H2O (up to 40 ml).
PCR reaction conditions were listed in Table 1. All PCR products
were analyzed using 1.0% agar gel electrophoresis and DNA
sequencing using a ABI 3730L automated sequencer (PE Bio-
systems, CT, USA). The data was analyzed using the DNAstar
(DNASTAR Inc., Madison, WI, USA). The 3D7 K13-propeller and
PfATPase6 sequences were used as the references.
2.5. Data analysis
The data was analyzed using SPSS 17.0 (SPSS Inc., Chicago, IL).
The mutant and wild-type alleles of the collected clinical samples
were used to generate the prevalence of the alleles. A two-tailed P-
value is less than 0.05 was considered statistically signiﬁcant. The
95% conﬁdence intervals (95% CI) was calculated as described
previously (Li et al., 2014).3. Results
3.1. K13-propeller polymorphisms
Sequence of a total of 98 (90.74%, 98/108) K13-propeller nested
PCR products was obtained from 108 (62.79%, 108/172) PCR-
positive samples out of the 172 isolates. The K13-propeller SNPs
were analyzed by comparing with the reference 3D7 strain
Fig. 1. Geographical map of Bioko Island, Equatorial Guinea.
Table 1
Primers and PCR conditions for genotyping.
Gene Primer Sequence (50e30) Size (bp) Mutation PCR condition
K13-propeller 1st round PCR
K13-1 CGGAGTGACCAAATCTGGGA 2097 95 C 3 min; followed by 30
cycles (95 C 30 s, 55 C 30 s,
72 C 30 s); 72 C 5 min; then
store 12 C.
K13-4 GGGAATCTGGTGGTAACAGC
2nd round PCR
PfK13_inF2 TCAACAATGCTGGCGTATGTG 501 T474I, M476I, A481V, Y493H,
T508N, P527T, G533S, N537I,
R539T, I543T, P553L, R561H,
V568G, P574L, A578S, and
C580Y
95 C 3 min; followed by 30
cycles (95 C 30 s, 55 C 30 s,
72 C 30 s); 72 C 5 min; then
store 12 C.
PfK13_inR2 TGATTAAG GTAATTAAAAGCTGCTCC
PfATPase6 1st round PCR
PfATPase6-N1F AATATTGTTATTCAGAATATGATTATAA 896 95 C 3 min; followed by 30
cycles (95 C 30 s, 55 C 30 s,
72 C 50 s); 72 C 5 min; then
store 12 C.
PfATPase6-N1R TGGATCAATAATACCTAATCCACCTA
2nd round PCR
PfATPase6-N2F AGCAAATATTTTCTGTAACGATAATA 798 K561N, N569K, A623E, A630S,
G639D, N683K, I723V, and
S769N
95 C 3 min; followed by 30
cycles (95 C 30 s, 58 C 30 s,
72 C 45 s); 72 C 5 min; then
store 12 C.
PfATPase6-N2R TGTTCTAATTTATAATAATCATCTGT
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position 578. The frequency of A578S was 2.04% (2/98) (Table 2).
No K13-propeller mutation was detected at positions 474, 476, 493,
508, 527, 537, 539, 543, 553, 561, 568, 574, and 580. Notably, the
C580Y, R539T, and Y493H substitutions that were associated with
ART resistance in vitro or delayed P. falciparum parasite clearance
in vivo in SE Asia were not detected on the samples from Bioko
Island, EG.3.2. PfATPase6 polymorphisms
Sequence of a total of 139 (91.45%, 139/152) PfATPase6 nested
PCR products was obtained from 152 (88.37%, 152/172) PCR-
positive samples out of the 172 isolates. The PfATPase6 SNPs were
analyzed by comparing with the reference 3D7 strain
(PF3D7_0106300) and listed in Table 2. The PfATPase6 SNPs were
found at positions N569K and A630S with the mutation prevalence
Table 2
K13-propeller and PfATPase6 polymorphisms in Plasmodium falciparum isolates on Bioko Island, Equatorial Guinea.
Gene Reference No. of isolates
Codon position AA Codon AA Codon Base position PCR positive Sequencing Mutation Prevalence (%, 95% CI)
K13-propeller 578 A gct S Tct 1732 108 98 2 2.04, 0.76 to 4.84
PfATPase6 569 N aaa K aaT 1707 152 139 11 7.91, 3.42 to 12.4
630 A gct S Tct 1888 152 139 2 1.44, 0.54 to 3.42
723 I ata V Gta 2167 152 139 1 0.72, 0.69 to 2.13
Bold, AA and No. represent single nucleotide polymorphism mutation, amino acid residue and number.
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addition, a sample with the mixed type at position I723V was also
discovered with the mutation prevalence of 1 (0.72%, 1/139)
(Table 2). The remaining mutations of K561N, A623E, G639D,
N683K, and S769N, all the investigated samples veriﬁed the wild-
type genotype. Notably, the S769N substitution that was con-
nected with ART resistance was not found from these samples.4. Discussion
For EG, both the AS-AQ and DP are considered as the front-line
treatment for uncomplicated falciparum malaria. It is essential to
understandmolecular mutation proﬁles of P. falciparum parasite for
ART resistance and use this initial information for molecular
assessment under antimalarial drug pressure. In current study, we
only ﬁnd limited mutation of K13-propeller and low frequency of
PfATPase6 mutation of the clinical isolates from Bioko Island, EG. It
is the initial report focusing on the molecular markers of K13-
propeller and PfATPase6 for ART resistance on this Island.
The ART resistance considers as a major risk to public health,
with the most rigorous potential effect in Sub-Saharan Africa,
where the burden is seriously. Furthermore, the international in-
vestments and domestic investments, the prevention and elimi-
nation system for malaria are also insufﬁcient in the region. The
hazard of ART-resistant parasites scattering from western
Cambodia to the Greater Mekong Subregion and then to Africa
particularly Sub-Saharan Africa, as happened previously with CQ
and SP-resistant parasites (Wootton et al., 2002; Roper et al., 2004),
is worrying (Ariey et al., 2014). A signiﬁcant action of the WHO
Global Plan for Artemisinin Resistance Containment is to increase
monitoring and molecular surveillance (Talisuna et al., 2012).
However, it is difﬁcult to evaluate how long or when ART resistance
mutations will appear in Africa including EG, and molecular
detection can offer a proﬁle to speedily discover for the appearance
or importation of resistance alleles (Taylor et al., 2014). In SE Asia,
the mutations of K13-propeller are found in both western Cambodia
(Ariey et al., 2014; Straimer et al., 2015) and Bangladesh (Mohon
et al., 2014). In Africa, only limited polymorphisms of K13-
propeller are detected (Conrad et al., 2014; Taylor et al., 2014;
Torrentino-Madamet et al., 2014). However, the K13-propeller
polymorphism in returned migrant workers from Ghana is found
in Shanglin of China (Feng et al., 2015). Thus, it is very necessary to
strengthen Plasmodium parasites genotypic resistance surveillance
with K13-propeller polymorphism. If there is no sufﬁcient attention
to long-term survey, it will be a disaster for human health.
The survey of P. falciparum K13-propeller polymorphisms pri-
marily explore a diversity of mutations across on Bioko Island, EG.
Limited polymorphisms associated with ART resistance from SE
Asia are observed in the clinical isolates. Recent study reports that
the SNP mutations at Y493H, I543T, R539T, and C580Y are power-
fully connected with prolonging P. falciparum parasite survival time
ex vivo; ART resistance in vitro has to be M476I mutation-related,
which indicates that mutations of K13-propeller can generate an
ART-resistance phenotype in vitro with genetic background fromAfrican parasite (Ariey et al., 2014). Although the ﬁve mutations
play crucial role during ART-resistance to P. falciparum parasite
in vitro and in vivo, we observe none of these mutations in the
survey parasite samples. Only one K13-propeller A578S mutation
(2.04%, 2/98) that previously reported from Cambodia is discovered
in the six K13-propeller blades. This mutation is previously found in
0.75% (1/133) of the isolates tested in Uganda and also presents in
parasites from DRC, Gabon, Ghana, Kenya, and Mali (Ariey et al.,
2014; Conrad et al., 2014; Kamau et al., 2015). Although the prev-
alence of A578Smutant allele from Bioko Island is lower than Kenya
at 2.7%, it is still higher in parasites compared to 1% in the other four
countries of Sub-Saharan Africa. This unusual polymorphism also
merits further characterization (Taylor et al., 2014). Mutations of
A481V, G533C and A578S are conﬁrmed and adjacent to the Y493H,
R539T, C580Y mutation, and propose the mutations may have a
signiﬁcant effect on three-dimensional structure of the K13-
propeller. Furthermore, the mutations of S522S, Y558H report in
Ugandan children and A557S in Congo have not detected on Bioko
Island (Conrad et al., 2014; Taylor et al., 2014). The V520A mutation
identiﬁed from West, Central and East Africa is also not found on
the Island, Dakar and Uganda (Sylla et al., 2013; Taylor et al., 2014).
These results encourage and suggest ART resistance is not yet
established in Africa particular on Bioko Island, EG. Although none
of the mutations associated with ART resistance in SE Asia are
detected in Africa (Conrad et al., 2014; Taylor et al., 2014),
numerous novel K13-propeller coding substitutions bothers in the
whole continent of Africa. The phenotypes of these coding poly-
morphisms remain unclear and will require further characteriza-
tion to better characterize the clinical impact on ART resistance in
Africa. Further analysis of phylogenetic tree or haplotype network is
needed to trace the origin of the K13-propeller mutations and to
determine whether the ART resistance is widely spreaded from SE
Asia or emerged independently in Bioko Island, EG (Nyunt et al.,
2014).
Polymorphisms evaluation of PfATPase6 in Africa have occurred
rarely (Mugittu et al., 2006; Legrand et al., 2008; Happi et al., 2009;
Menegon et al., 2010; Kamugisha et al., 2011; Zatra et al., 2012). The
current study initial describes for the PfATPase6 polymorphism on
Bioko Island, EG. Among the three different observed mutations,
only one, the N569K mutation, is relatively frequent 7.91% of iso-
lates. The previous studies have also found a high prevalence of this
mutation in Zanzibar (36%) and Tanzania (29%) (Dahlstrom et al.,
2008), Niger (17.2%) (Ibrahim et al., 2009). The PfATPase6 S769N
mutation is absent in all Bioko samples and consistent with pre-
vious results in Africa countries (Mugittu et al., 2006; Legrand et al.,
2008; Happi et al., 2009; Menegon et al., 2010; Kamugisha et al.,
2011; Zatra et al., 2012) and South America (Adhin et al., 2012). It
demonstrates that the Africa and South America share the similar
molecular pattern of PfATPase6 for ART resistance.5. Conclusions
The present study shows that the low prevalence polymorphism
mutations of PfATPase6 and limited mutations of K13-propeller,
J. Li et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 54e5958potentially associated with ART resistance, are obviously observed
on Bioko Island, EG. Continuous molecular surveillance with K13-
propeller gene as ART resistance marker is exceedingly recom-
mended on Bioko Island, EG. Furthermore, it might be helpful for
developing and updating guidance for the use of ACTs.
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